Compare AMC ENTERTAINMENT HOLDINGS, INC. (AMC) vs Cytokinetics Inc (CYTK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AMC ENTERTAINMENT HOLDINGS, INC. vs Cytokinetics Inc — how do they compare? AMC ENTERTAINMENT HOLDINGS, INC. trades at $2.47 (market cap $2.14B), while Cytokinetics Inc trades at $76.43 (market cap $10.63B). The key difference: Cytokinetics Inc is far larger — about 5× AMC ENTERTAINMENT HOLDINGS, INC.'s market cap, and AMC ENTERTAINMENT HOLDINGS, INC. pays a 0.11% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| AMC | CYTK | |
|---|---|---|
Market Cap | $2.14B | $10.63B |
Sector | Media | Technology |
52-Week High | $3.15 | $87.26 |
52-Week Low | $0.95 | $34.31 |
Enterprise Value | $9.08B | $10.74B |
Dividend Yield | 0.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMC trades at $2.42, down 6.56% today, yet maintains a bullish technical signal with strong recent earnings beats. The company reported record Q2 2026 revenue and EBITDA, driven by surging attendance and premium screen growth. However, negative net income and substantial debt of $4.01 billion highlight financial strain. Analyst consensus is a $3.00 price target with mixed ratings (32% Buy, 46% Hold).
The outlook hinges on sustained box office recovery and cash flow improvement, with management citing a potential cash-flow breakthrough. Key risks include high leverage, dependence on film slate success, and meme-stock volatility. Upside exists if operational momentum continues, but the negative equity position warrants caution.
CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.
The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AMC ENTERTAINMENT HOLDINGS, INC.
AMC Entertainment Holdings, Inc. operates as a holding company. The Company, through its subsidiaries, provides theatrical exhibition, movie screening, food distribution, online ticket booking, and other related services. AMC Entertainment offers movie theaters worldwide.
Read more on AMC →About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →
